66 related articles for article (PubMed ID: 19962343)
21. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.
Vaz P; Chaix ML; Jani I; Macassa E; Bila D; Vubil A; Anderson S; Rouzioux C; Briand N; Blanche S
Pediatr Infect Dis J; 2009 Dec; 28(12):e283-7. PubMed ID: 19907359
[TBL] [Abstract][Full Text] [Related]
22. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
23. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
24. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy.
Wunder DM; Bersinger NA; Fux CA; Mueller NJ; Hirschel B; Cavassini M; Elzi L; Schmid P; Bernasconi E; Mueller B; Furrer H;
Antivir Ther; 2007; 12(2):261-5. PubMed ID: 17503668
[TBL] [Abstract][Full Text] [Related]
25. Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
Leporrier J; Etienne M; Chapuzet C; Peytavin G; Bord S; Borsa-Lebas F; Caron F; Plantier JC; Mourez T
J Clin Virol; 2014 Aug; 60(4):428-30. PubMed ID: 24932736
[TBL] [Abstract][Full Text] [Related]
26. Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.
Boutolleau D; Canestri A; Burrel S; Wirden M; Seang S; Clavel-Osorio C; Marcelin AG; Katlama C; Agut H
J Clin Virol; 2012 Jun; 54(2):194-6. PubMed ID: 22398036
[TBL] [Abstract][Full Text] [Related]
27. Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations.
Mathiesen S; Roge BT; Weis N; Lundgren JD; Obel N; Gerstoft J
AIDS; 2004 Apr; 18(7):1076-8. PubMed ID: 15096815
[No Abstract] [Full Text] [Related]
28. Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs.
Di Biagio A; Bruzzone B; Rosso R; Viganò O; Icardi G; Viscoli C; Rusconi S
AIDS Patient Care STDS; 2008 May; 22(5):355-7. PubMed ID: 18373415
[No Abstract] [Full Text] [Related]
29. Pronounced anti-HIV-1 activity of foscarnet in patients without cytomegalovirus infection.
Bergdahl S; Jacobsson B; Moberg L; Sönnerborg A
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 May; 18(1):51-3. PubMed ID: 9593458
[TBL] [Abstract][Full Text] [Related]
30. Long-term maraviroc use as salvage therapy in HIV-2 infection.
Caixas U; Ferreira J; Marinho AT; Faustino I; Grilo NM; Lampreia F; Germano I; Monteiro EC; Pereira SA
J Antimicrob Chemother; 2012 Oct; 67(10):2538-9. PubMed ID: 22729923
[No Abstract] [Full Text] [Related]
31. More on virostatic therapy for advanced lymphoproliferation associated with Epstein-Barr virus in an HIV-infected patient.
MacMahon EM
N Engl J Med; 2000 Jul; 343(1):71-2. PubMed ID: 10896553
[No Abstract] [Full Text] [Related]
32. Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from dual therapy studies.
Ripamonti D; Zazzi M
AIDS; 2018 Apr; 32(7):835-840. PubMed ID: 29424781
[No Abstract] [Full Text] [Related]
33. Changes in HIV-1 RNA plasma level in patients treated with foscarnet.
Segondy M; Montes B; Delmas B; Leclercq C; Janbon F; Reynes J
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jan; 14(1):79-80. PubMed ID: 8989215
[No Abstract] [Full Text] [Related]
34. Virostatic therapy for advanced lymphoproliferation associated with the Epstein-Barr virus in an HIV-infected patient.
Schmidt W; Anagnostopoulos I; Scherübl H
N Engl J Med; 2000 Feb; 342(6):440-1. PubMed ID: 10681228
[No Abstract] [Full Text] [Related]
35. Foscarnet-associated eosinophilic folliculitis in a patient with AIDS.
Roos TC; Albrecht H
J Am Acad Dermatol; 2001 Mar; 44(3):546-7. PubMed ID: 11209138
[No Abstract] [Full Text] [Related]
36. Effectiveness of rescue antiretroviral therapy including intravenously administered zidovudine and foscarnet in a child with HIV-1 enteropathy.
Hainaut M; Gérard M; Peltier CA; Souayah H; Mascart F; Zissis G; Levy J
Eur J Pediatr; 2003 Jul; 162(7-8):528-529. PubMed ID: 12739138
[No Abstract] [Full Text] [Related]
37. Foscarnet for suppression of human immunodeficiency virus replication.
Fletcher CV; Collier AC; Rhame FS; Bennett D; Para MF; Beatty CC; Jones CE; Balfour HH
Antimicrob Agents Chemother; 1994 Mar; 38(3):604-7. PubMed ID: 7911290
[TBL] [Abstract][Full Text] [Related]
38. Anti-viral therapy for lymphoma.
TreatmentUpdate; 2000 Sep; 12(6):5-6. PubMed ID: 12132462
[No Abstract] [Full Text] [Related]
39. Foscarnet-induced vulvar erosion.
Caumes E; Gatineau M; Bricaire F; Dohin E; Katlama C; Gentilini M
J Am Acad Dermatol; 1993 May; 28(5 Pt 1):799. PubMed ID: 8496435
[No Abstract] [Full Text] [Related]
40. Foscarnet treatment of chronic hepatitis B in an HIV-positive patient.
Antinori S; Esposito R; d'Arminio Monforte A; Moroni M
J Hepatol; 1993 Jun; 18(2):255-6. PubMed ID: 8409341
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
